Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

Y. Wang,X. Ma,Y. Guo,X. Li

DOI: https://doi.org/10.1016/j.ijrobp.2015.07.1696

2015-01-01

Abstract:Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is an aggressive entity of non-Hodgkin's lymphoma with poor prognosis. ENKTL is sensitive to radiation but resistant to anthracycline-containing chemotherapy. This study aims to evaluate the efficacy of the chemoradiation therapy composed of DICE regimen and regional field radiation therapy in early stage ENTKL. In this study, we employed DICE regimen (dexamethasone, ifosfamide, mensa, cisplatin and etoposide) chemotherapy followed by regional field radiation therapy to treat patients with stages I ENKTL with risk factors in the upper aerodigestive tract and stage II ENKTL with cervical lymph nodes involved. The risk factors included elevated LDH, B symptom, ECOG≥2 and locally extensive disease involved more than two anatomic structures. Inductive chemotherapy was given 2 to 4 cycles and radiation was delivered with intensity-modulated radiation therapy (IMRT) to a prescribed dose of 50 Gy in 25 fractions. Treatment toxicities, locoregional, and systemic failure were observed, while treatment response and survival data were analyzed as well. In the cohort of 118 patients who met the enrollment criteria, 28.8% patients achieved complete response (CR) and 41.5% had partial response (PR) after DICE treatment. Subsequently, the CR rate climbed to 90.7%, with the PR rate of 6.8% after completion of definitive radiation therapy (RT). Patients tolerated chemotherapy and radiation therapy well. Grade II-III neutrophilic granulocytopenia was the main toxicity after chemotherapy. Long term mild xerostomia and hypogeusia after radiation therapy were observed in few patients. Among the patients who had CR after RT, 11 of them got local relapses in 3-46 months after the start of treatment, with the 5-year local control rate of 90.2%. Thirty-two patients developed systemic disseminations in 3-72 months after treatment. The most frequent recurrent site was skin, followed by organs in abdominopelvic cavity and central nervous system. Except for one patient died of diabetes and one died of secondary malignance, all the other 34 dead patients had distant metastasis or hemophagocytosis, with four concurrent local relapses. Totally, within a median follow-up time of 68 months (3-88 months), the 5-year overall survival (OS) and progression free survival (PFS) were 71.3% and 62.4%, respectively. In conclusion, DICE chemotherapy followed by involved field radiation therapy is a feasible and effective treatment for newly diagnosed stages I-II ENKTL.